Ipsen’s Onivyde SCLC Dreams Die With Phase III Failure, Focus Shifts To Pancreatic

Stumble In Plans To Expand Label

 
• By Ayisha Sharma

The French firm’s Onivyde has missed the mark in an advanced small-cell lung cancer Phase III trial, prompting the firm to tout the drug’s prospects in a large pancreatic cancer indication instead.  

Image of an IV drip, often used in chemotherapy
Onivyde Is Being Studied In Combination With Traditional Chemotherapy Drugs • Source: Shutterstock

More from Clinical Trials

More from R&D